CLINICAL_TRIALS
trial_result
· 2020-06-02
Clinical Trial Update: Clinical Endpoint Study of Ivermectin 1% Cream [Phase 3]
Summary
Phase 3 clinical trial of ivermectin 1% cream for moderate to severe papulopustular rosacea completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Actavis Inc. | Conditions: Moderate to Severe Papulopustular Rosacea | Phase 3 | Status: COMPLETED | Results posted: 2020-06-02